(function(){var loadHandler=window['sl_{FA5FD24E-B284-45DA-9AF0-EFB2D448B75A}'];loadHandler&&loadHandler(1, '<div id="spr0_5cf6c2f8"><div id="spr1_5cf6c2f8" class="kern slide"><img id="img12_5cf6c2f8" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_5cf6c2f8" class="kern slide"><img id="img0_5cf6c2f8" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_5cf6c2f8" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_5cf6c2f8" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_5cf6c2f8" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_5cf6c2f8" style="left:657.715px;top:499.855px;"><img id="img2_5cf6c2f8" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_5cf6c2f8" style="left:-1.875px;top:30.156px;"><div style="width:0px;"><span id="txt0_5cf6c2f8" data-width="670.671875" style="left:25.54px;top:5.086px;">When to Consider Additional Lipid Lowering  Therapy</span></div></div><div id="svg4_5cf6c2f8" style="left:616.346px;top:336.329px;"><svg width="46" height="42" viewBox="0 0 46 42"><path fill="#ccd1de" d="M0,31.101 v-20.734 L24.57,10.367 v-10.367 l20.734,20.734 l-20.734,20.734 v-10.367 Z"/></svg></div><div id="svg5_5cf6c2f8" style="left:290.764px;top:337.741px;"><svg width="46" height="42" viewBox="0 0 46 42"><path fill="#b8bfd0" d="M0,31.101 v-20.734 L24.57,10.367 v-10.367 l20.734,20.734 l-20.734,20.734 v-10.367 Z"/></svg></div><div id="svg6_5cf6c2f8" style="left:616.346px;top:279.018px;"><svg width="46" height="42" viewBox="0 0 46 42"><path fill="#f9d783" d="M0,31.101 v-20.734 L24.57,10.367 v-10.367 l20.734,20.734 l-20.734,20.734 v-10.367 Z"/></svg></div><div id="svg7_5cf6c2f8" style="left:289.09px;top:280.43px;"><svg width="46" height="42" viewBox="0 0 46 42"><path fill="#f6c448" d="M0,31.101 v-20.734 L24.57,10.367 v-10.367 l20.734,20.734 l-20.734,20.734 v-10.367 Z"/></svg></div><div id="svg9_5cf6c2f8" style="left:588.551px;top:144.019px;"><svg width="26" height="25" viewBox="-0 -0 26 25"><g fill="none"><path fill="#bfbfbf" transform="matrix(-0,1,-1,-0,25.953465,0.000001)" d="M0,19.465 v-12.977 L12.087,6.488 v-6.488 l12.087,12.977 l-12.087,12.977 v-6.488 Z"/></g></svg></div><img id="img3_5cf6c2f8" src="data/img5.png" width="676.183" height="22.68" alt="" style="left:16.402px;top:120.956px;"/><div id="spr5_5cf6c2f8" style="left:16.402px;top:120.956px;"><div style="width:0px;"><span id="txt1_5cf6c2f8" class="nokern" data-width="331.214844" style="left:8.307px;top:3.59px;">                                                         Statin-Indicated Conditions</span></div></div><div id="spr6_5cf6c2f8" style="left:15.686px;top:192.316px;"><img id="img4_5cf6c2f8" src="data/img6.png" width="676.899" height="22.617" alt=""/></div><div id="spr7_5cf6c2f8" style="left:15.686px;top:192.316px;"><div style="width:0px;"><span id="txt2_5cf6c2f8" class="nokern" data-width="278.113281" style="left:198.887px;top:3.559px;">Initiate Statin Treatment : Treat to Target Approach</span></div></div><div id="svg12_5cf6c2f8" style="left:15.686px;top:214.932px;"><svg width="677" height="46" viewBox="0 0 677 46"><path fill="#ebedf1" d="M0,0 h676.899 v45.422 h-676.899 Z"/></svg></div><div id="spr8_5cf6c2f8" style="left:507px;top:213px;"><img id="img5_5cf6c2f8" src="data/img7.png" width="8" height="52" alt=""/></div><div id="spr9_5cf6c2f8" style="left:17.686px;top:217.747px;"><div style="width:0px;"><span id="txt3_5cf6c2f8" class="nokern relpos" data-width="103.044922" style="left:90.625px;top:4.401px;">LDL-C &lt;2.0 mmol/L </span><span id="txt4_5cf6c2f8" class="nokern relpos" data-width="14.669922" style="left:90.62px;top:4.25px;">or </span><span id="txt5_5cf6c2f8" class="nokern relpos" data-width="86.488281" style="left:90.615px;top:4.401px;"> &gt;50% reduction </span><span id="txt6_5cf6c2f8" class="nokern relpos" data-width="11.477539" style="left:90.61px;top:4.25px;">or</span><span id="txt7_5cf6c2f8" class="nokern relpos" data-width="78.209961" style="left:90.605px;top:4.401px;"> apoB &lt;0.8 g/L </span><span id="txt8_5cf6c2f8" class="nokern relpos" data-width="11.477539" style="left:90.6px;top:4.25px;">or</span></div><div style="width:0px;"><span id="txt9_5cf6c2f8" class="nokern" data-width="124.099609" style="left:181.625px;top:21.171px;">non HDL-C &lt;2.6 mmol/L</span></div></div><div id="spr10_5cf6c2f8" style="left:512.487px;top:226.221px;"><div style="width:0px;"><span id="txt10_5cf6c2f8" class="nokern" data-width="116.457031" style="left:29.26px;top:4.371px;">LDL-C &gt;50% reduction</span></div></div><div id="spr11_5cf6c2f8" style="left:16.402px;top:268.695px;"><img id="img6_5cf6c2f8" src="data/img6.png" width="676.899" height="22.617" alt=""/></div><div id="spr12_5cf6c2f8" style="left:16.402px;top:268.695px;"><div style="width:0px;"><span id="txt11_5cf6c2f8" class="nokern" data-width="252.034180" style="left:212.137px;top:3.559px;">Target achieved on maximally tolerated dose?</span></div></div><div id="spr13_5cf6c2f8" style="left:16.402px;top:325.734px;"><img id="img7_5cf6c2f8" src="data/img8.png" width="676.899" height="22.617" alt=""/></div><div id="spr14_5cf6c2f8" style="left:16.402px;top:325.734px;"><div style="width:0px;"><span id="txt12_5cf6c2f8" class="nokern" data-width="197.121094" style="left:239.7px;top:3.559px;">Discuss add-on therapy with patient</span></div></div><div id="spr15_5cf6c2f8" style="left:247.622px;top:295.948px;"><div style="width:0px;"><span id="txt13_5cf6c2f8" class="nokern" data-width="12.914795" style="left:14.234px;top:4.088px;">NO</span></div></div><div id="spr16_5cf6c2f8" style="left:16.402px;top:381.15px;"><img id="img8_5cf6c2f8" src="data/img8.png" width="676.899" height="22.617" alt=""/></div><div id="spr17_5cf6c2f8" style="left:16.402px;top:381.15px;"><div style="width:0px;"><span id="txt14_5cf6c2f8" class="nokern" data-width="88.012695" style="left:294.45px;top:3.559px;">Add-on Therapy</span></div></div><div id="svg16_5cf6c2f8" style="left:16.402px;top:403.594px;"><svg width="677" height="52" viewBox="0 0 677 52"><path fill="#ebedf1" d="M0,0 h676.899 v51.32 h-676.899 Z"/></svg></div><div id="spr18_5cf6c2f8" style="left:17.686px;top:408.552px;"><div style="width:0px;"><span id="txt15_5cf6c2f8" class="nokern relpos" data-width="75.304688" style="left:140.862px;top:4.371px;">Ezetimibe as 1</span><span id="txt16_5cf6c2f8" class="nokern relpos" data-width="5.956380" style="left:140.857px;top:4.473px;">st</span><span id="txt17_5cf6c2f8" class="nokern relpos" data-width="126.348633" style="left:140.852px;top:4.371px;"> line (BAS as alternative)</span></div><div style="width:0px;"><span id="txt18_5cf6c2f8" class="nokern relpos" data-width="111.671875" style="left:113.987px;top:21.171px;">PCSK9 inhibitors as 2</span><span id="txt19_5cf6c2f8" class="nokern relpos" data-width="8.513021" style="left:113.982px;top:21.273px;">nd</span><span id="txt20_5cf6c2f8" class="nokern relpos" data-width="141.052734" style="left:113.977px;top:21.171px;"> line (add on to other drugs)</span></div></div><div id="spr19_5cf6c2f8" style="left:509.46px;top:408.68px;"><div style="width:0px;"><span id="txt21_5cf6c2f8" class="nokern" data-width="151.839844" style="left:14.315px;top:4.371px;">Ezetimibe (or BAS) or PCSK9</span></div><div style="width:0px;"><span id="txt22_5cf6c2f8" class="nokern" data-width="45.944336" style="left:67.38px;top:21.171px;">inhibitors</span></div></div><div id="spr20_5cf6c2f8" style="left:535.094px;top:140.101px;"><div style="width:0px;"><span id="txt23_5cf6c2f8" class="nokern" data-width="79.306641" style="left:30.926px;top:4.151px;">(genetic dyslipidemia)</span></div></div><div id="spr21_5cf6c2f8" style="left:16.686px;top:166.316px;"><img id="img9_5cf6c2f8" src="data/img6.png" width="676.899" height="22.617" alt=""/></div><div id="spr22_5cf6c2f8" style="left:16.686px;top:166.316px;"><div style="width:0px;"><span id="txt24_5cf6c2f8" class="nokern" data-width="182.478516" style="left:247.012px;top:3.559px;">Discuss behavioral modifications</span></div></div><div id="svg19_5cf6c2f8" style="left:254.319px;top:142.824px;"><svg width="26" height="25" viewBox="-0 -0 26 25"><g fill="none"><path fill="#404040" transform="matrix(-0,1,-1,-0,25.953465,0.000001)" d="M0,19.465 v-12.977 L10.413,6.488 v-6.488 l13.761,12.977 l-13.761,12.977 v-6.488 Z"/></g></svg></div><div id="spr23_5cf6c2f8" style="left:574.878px;top:296.326px;"><div style="width:0px;"><span id="txt25_5cf6c2f8" class="nokern" data-width="12.914795" style="left:14.234px;top:4.088px;">NO</span></div></div><div id="spr24_5cf6c2f8" style="left:249.297px;top:348.329px;"><div style="width:0px;"><span id="txt26_5cf6c2f8" class="nokern" data-width="14.203125" style="left:13.609px;top:3.972px;">ADD</span></div><div style="width:0px;"><span id="txt27_5cf6c2f8" class="nokern" data-width="9.839844" style="left:15.794px;top:13.572px;">ON</span></div></div><div id="spr25_5cf6c2f8" style="left:574.878px;top:348.688px;"><div style="width:0px;"><span id="txt28_5cf6c2f8" class="nokern" data-width="14.203125" style="left:13.609px;top:3.972px;">ADD</span></div><div style="width:0px;"><span id="txt29_5cf6c2f8" class="nokern" data-width="9.839844" style="left:15.794px;top:13.572px;">ON</span></div></div><div id="spr26_5cf6c2f8" style="left:504px;top:401px;"><img id="img10_5cf6c2f8" src="data/img9.png" width="8" height="57" alt=""/></div><div id="spr27_5cf6c2f8" style="left:15px;top:118px;"><div style="width:0px;"><span id="txt30_5cf6c2f8" class="nokern relpos" style="left:10.007px;top:53.742px;"></span><span id="txt31_5cf6c2f8" class="nokern relpos" data-width="307.839844" style="left:26.027px;top:52.934px;">LDL-C&lt;15-20% away from target:</span></div><div style="width:0px;"><span id="txt32_5cf6c2f8" class="nokern relpos" style="left:46.007px;top:81.763px;">─</span><span id="txt33_5cf6c2f8" class="nokern relpos" data-width="361.875000" style="left:58.398px;top:81.548px;">addition of ezetimibe is likely to achieve target</span></div><div style="width:0px;"><span id="txt34_5cf6c2f8" class="nokern relpos" style="left:10.007px;top:130.542px;"></span><span id="txt35_5cf6c2f8" class="nokern relpos" data-width="284.871094" style="left:26.027px;top:129.734px;">LDL-C&gt; 20% away from target:</span></div><div style="width:0px;"><span id="txt36_5cf6c2f8" class="nokern relpos" style="left:46.007px;top:158.563px;">─</span><span id="txt37_5cf6c2f8" class="nokern relpos" data-width="546.806641" style="left:58.398px;top:158.348px;">no add-on drug other than a PCSK9 inhibitor is likely to achieve target</span></div><div style="width:0px;"><span id="txt38_5cf6c2f8" class="nokern relpos" style="left:10.007px;top:207.342px;"></span><span id="txt39_5cf6c2f8" class="nokern relpos" data-width="574.183594" style="left:26.027px;top:206.534px;">Use clinician judgement and patient-centered approach when</span></div><div style="width:0px;"><span id="txt40_5cf6c2f8" class="nokern" data-width="596.003906" style="left:37.007px;top:235.334px;">adding non-statin therapy (i.e. ezetimibe first, PCSK9 inhibitors,</span></div><div style="width:0px;"><span id="txt41_5cf6c2f8" class="nokern" data-width="54.644531" style="left:37.007px;top:264.134px;">both).</span></div></div><div id="spr28_5cf6c2f8" style="left:15px;top:118px;"><img id="img11_5cf6c2f8" src="data/img10.png" width="687" height="343" alt=""/></div><div id="spr29_5cf6c2f8" style="left:15px;top:118px;"><div style="width:0px;"><span id="txt42_5cf6c2f8" class="nokern relpos" style="left:7.886px;top:51.621px;"></span><span id="txt43_5cf6c2f8" class="nokern relpos" data-width="307.839844" style="left:23.906px;top:50.812px;">LDL-C&lt;15-20% away from target:</span></div><div style="width:0px;"><span id="txt44_5cf6c2f8" class="nokern relpos" style="left:43.886px;top:79.641px;">─</span><span id="txt45_5cf6c2f8" class="nokern relpos" data-width="361.875000" style="left:56.277px;top:79.427px;">addition of ezetimibe is likely to achieve target</span></div><div style="width:0px;"><span id="txt46_5cf6c2f8" class="nokern relpos" style="left:7.886px;top:128.421px;"></span><span id="txt47_5cf6c2f8" class="nokern relpos" data-width="284.871094" style="left:23.906px;top:127.612px;">LDL-C&gt; 20% away from target:</span></div><div style="width:0px;"><span id="txt48_5cf6c2f8" class="nokern relpos" style="left:43.886px;top:156.441px;">─</span><span id="txt49_5cf6c2f8" class="nokern relpos" data-width="546.806641" style="left:56.277px;top:156.227px;">no add-on drug other than a PCSK9 inhibitor is likely to achieve target</span></div><div style="width:0px;"><span id="txt50_5cf6c2f8" class="nokern relpos" style="left:7.886px;top:205.221px;"></span><span id="txt51_5cf6c2f8" class="nokern relpos" data-width="574.183594" style="left:23.906px;top:204.412px;">Use clinician judgement and patient-centered approach when</span></div><div style="width:0px;"><span id="txt52_5cf6c2f8" class="nokern" data-width="596.003906" style="left:34.886px;top:233.212px;">adding non-statin therapy (i.e. ezetimibe first, PCSK9 inhibitors,</span></div><div style="width:0px;"><span id="txt53_5cf6c2f8" class="nokern" data-width="54.644531" style="left:34.886px;top:262.012px;">both).</span></div></div><div id="spr30_5cf6c2f8" style="left:-0.439px;top:506.646px;"><div style="width:0px;"><span id="txt54_5cf6c2f8" class="nokern" data-width="215.629883" style="left:7.2px;top:4.151px;">Anderson and al., Can Journal of Cardiol, 32 (11); 1263-82.</span></div></div><div id="spr31_5cf6c2f8" style="left:219.324px;top:507.604px;"><div style="width:0px;"><span id="txt55_5cf6c2f8" class="nokern" data-width="418.273438" style="left:7.2px;top:4.205px;">Apo, apolipoprotein; BAS, bile acid sequestrant; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.</span></div></div></div></div>');})();